New approaches to screening and management of neonatal hypoglycemia based on improved understanding of the molecular mechanism of hypoglycemia.

brain damage glucose insulin ketones newborns

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2023
Historique:
received: 15 10 2022
accepted: 23 02 2023
entrez: 27 3 2023
pubmed: 28 3 2023
medline: 28 3 2023
Statut: epublish

Résumé

For the past 70 years, controversy about hypoglycemia in newborn infants has focused on a numerical "definition of neonatal hypoglycemia", without regard to its mechanism. This ignores the purpose of screening newborns for hypoglycemia, which is to identify those with pathological forms of hypoglycemia and to prevent hypoglycemic brain injury. Recent clinical and basic research indicates that the three major forms of neonatal hypoglycemia are caused by hyperinsulinism (recognizing also that other rare hormonal or metabolic conditions may also present during this time frame). These include transitional hypoglycemia, which affects all normal newborns in the first few days after birth; perinatal stress-induced hypoglycemia in high-risk newborns, which afflicts ∼1 in 1,200 newborns; and genetic forms of congenital hyperinsulinism which afflict ∼1 in 10,000-40,000 newborns. (1) Transitional hyperinsulinism in normal newborns reflects persistence of the low glucose threshold for insulin secretion during fetal life into the first few postnatal days. Recent data indicate that the underlying mechanism is decreased trafficking of ATP-sensitive potassium channels to the beta-cell plasma membrane, likely a result of the hypoxemic state of fetal life. (2) Perinatal stress-induced hyperinsulinism in high-risk infants appears to reflect an exaggeration of this normal low fetal glucose threshold for insulin release due to more severe and prolonged exposure to perinatal hypoxemia. (3) Genetic hyperinsulinism, in contrast, reflects permanent genetic defects in various steps controlling beta-cell insulin release, such as inactivating mutations of the

Identifiants

pubmed: 36969273
doi: 10.3389/fped.2023.1071206
pmc: PMC10036912
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1071206

Informations de copyright

© 2023 Stanley, Thornton and De Leon.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer VS declared shared affiliation with one of the authors DDDL to the handling editor at the time of the review.

Références

J Pediatr Nurs. 2005 Apr;20(2):109-18
pubmed: 15815570
N Engl J Med. 1968 Jun 6;278(23):1260-2
pubmed: 5689621
J Clin Endocrinol Metab. 2009 Mar;94(3):709-28
pubmed: 19088155
J Pediatr. 2015 Jun;166(6):1520-5.e1
pubmed: 25819173
Diabetes. 2001 Feb;50(2):322-8
pubmed: 11272143
J Clin Invest. 2005 Apr;115(4):1006-15
pubmed: 15761495
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3038-43
pubmed: 24516164
Nat Biotechnol. 2012 Feb 26;30(3):261-4
pubmed: 22371083
Diabetes. 1977 Nov;26(11):1016-23
pubmed: 913891
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32810255
Diabet Med. 2000 Feb;17(2):91-104
pubmed: 10746478
JAMA Pediatr. 2017 Oct 1;171(10):972-983
pubmed: 28783802
N Engl J Med. 1998 May 7;338(19):1352-7
pubmed: 9571255
J Clin Invest. 2019 Jan 2;129(1):246-251
pubmed: 30507613
J Pediatr. 2021 Apr;231:81-86.e2
pubmed: 33373670
Front Pediatr. 2022 Oct 31;10:999274
pubmed: 36389353
Pediatrics. 2001 Mar;107(3):476-9
pubmed: 11230585
Pediatr Diabetes. 2018 Aug;19(5):910-916
pubmed: 29493090
Clin Perinatol. 2022 Mar;49(1):55-72
pubmed: 35210009
Curr Diab Rep. 2019 Sep 6;19(10):97
pubmed: 31493043
N Engl J Med. 1965 Aug 12;273(7):378-81
pubmed: 21417085
J Clin Endocrinol Metab. 2015 Nov;100(11):4133-9
pubmed: 26327482
Horm Res Paediatr. 2019;91(1):25-32
pubmed: 30889588
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4365-4372
pubmed: 30247666
JAMA. 2022 Mar 22;327(12):1158-1170
pubmed: 35315886
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1542-e1551
pubmed: 33475139
Lancet. 1984 Aug 11;2(8398):311-3
pubmed: 6146862
J Pediatr. 2006 Feb;148(2):207-12
pubmed: 16492430
N Engl J Med. 2001 Sep 27;345(13):971-80
pubmed: 11575290
N Engl J Med. 2020 Feb 27;382(9):835-844
pubmed: 32101665
Pediatrics. 1971 May;47(5):831-8
pubmed: 5573868
J Clin Endocrinol Metab. 2013 Feb;98(2):E355-63
pubmed: 23275527
Endocrinology. 2021 Sep 1;162(9):
pubmed: 34134142
N Engl J Med. 2015 Oct 15;373(16):1507-18
pubmed: 26465984
J Clin Endocrinol Metab. 2015 Dec;100(12):E1540-9
pubmed: 26431509
Diabetes. 2018 May;67(5):849-860
pubmed: 29440278
Lancet. 1965 Mar 6;1(7384):524-6
pubmed: 14254374
N Engl J Med. 2020 Feb 6;382(6):534-544
pubmed: 32023373
Pediatrics. 2000 May;105(5):1141-5
pubmed: 10790476
PLoS One. 2020 Feb 6;15(2):e0228417
pubmed: 32027664
J Pediatr. 2015 Aug;167(2):238-45
pubmed: 25957977
Front Physiol. 2019 Mar 06;10:148
pubmed: 30949058
J Pediatr. 2012 Nov;161(5):787-91
pubmed: 22727868
Front Endocrinol (Lausanne). 2013 May 20;4:60
pubmed: 23730298

Auteurs

Charles A Stanley (CA)

Congenital Hyperinsulinism Center and Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.

Paul S Thornton (PS)

Congenital Hyperinsulinism Center, Division of Endocrinology, Cook Children's Medical Center, Fort Worth, TX, United States.
Department of Pediatrics, Texas Christian University Burnett School of Medicine, Fort Worth, TX, United States.

Diva D De Leon (DD)

Congenital Hyperinsulinism Center and Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.

Classifications MeSH